Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Livermore

Showing results (31-40 of 269) with videos related to

Pageof 27
Sort By:
The Journal of Antimicrobial Chemotherapy|May 23, 2013
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosaDavid M Livermore, Marina Warner, Shazad Mushtaq
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance dataCarolyne Horner, Shazad Mushtaq, David M Livermore, et al.
International Journal of Antimicrobial Agents|December 24, 2013
Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococciDavid M Livermore, Marina Warner, Shazad Mushtaq
The Journal of Antimicrobial Chemotherapy|September 18, 2010
Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanismsDavid M Livermore, Shazad Mushtaq, Marina Warner
The Journal of Antimicrobial Chemotherapy|June 6, 2009
Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanismsDavid M Livermore, Shazad Mushtaq, Marina Warner
The Journal of Antimicrobial Chemotherapy|April 30, 2019
Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infectionsCarolyne Horner, Shazad Mushtaq, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|August 31, 2010
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermentersShazad Mushtaq, Marina Warner, David M Livermore
The Journal of Antimicrobial Chemotherapy|February 12, 2005
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenemsDavid M Livermore, Shazad Mushtaq, Marina Warner
Antimicrobial Agents and Chemotherapy|March 30, 2004
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamasesShazad Mushtaq, Yigong Ge, David M Livermore
The Journal of Antimicrobial Chemotherapy|July 4, 2002
In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocciAlan P Johnson, Marina Warner, David M Livermore
Pageof 27

Showing results (31-40 of 269) with videos related to

Sort By:
Pageof 27
The Journal of Antimicrobial Chemotherapy|May 23, 2013
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosaDavid M Livermore, Marina Warner, Shazad Mushtaq
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance dataCarolyne Horner, Shazad Mushtaq, David M Livermore, et al.
International Journal of Antimicrobial Agents|December 24, 2013
Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococciDavid M Livermore, Marina Warner, Shazad Mushtaq
The Journal of Antimicrobial Chemotherapy|September 18, 2010
Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanismsDavid M Livermore, Shazad Mushtaq, Marina Warner
The Journal of Antimicrobial Chemotherapy|June 6, 2009
Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanismsDavid M Livermore, Shazad Mushtaq, Marina Warner
The Journal of Antimicrobial Chemotherapy|April 30, 2019
Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infectionsCarolyne Horner, Shazad Mushtaq, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|August 31, 2010
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermentersShazad Mushtaq, Marina Warner, David M Livermore
The Journal of Antimicrobial Chemotherapy|February 12, 2005
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenemsDavid M Livermore, Shazad Mushtaq, Marina Warner
Antimicrobial Agents and Chemotherapy|March 30, 2004
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamasesShazad Mushtaq, Yigong Ge, David M Livermore
The Journal of Antimicrobial Chemotherapy|July 4, 2002
In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocciAlan P Johnson, Marina Warner, David M Livermore
Pageof 27